Abstract:Introduction: Accumulating evidence indicates that b romodomain and e xtra- t erminal domain (BET) proteins play a pivotal role in the transcriptional regulation of the inflammatory response, and consequently, BET inhibition has emerged as a promising novel therapeutic strategy to reduce inflammation linked to many diseases, including ischemic brain injury. dBET1 is the first BET-targeted proteolysis-targeting chimera (PROTAC) that induces a rapid and efficient deletion of BET proteins in vivo . Hypothesis: In this study, we hypothesized that dBET1 protects against brain damage and neurological deficits in a transient cerebral ischemia mouse model through the regulation of the inflammatory process. Methods: Adult C57BL/6 WT mice were subjected to transient cerebral ischemia surgery (tMCAO) and were administered intraperitoneally with dBET1 (30 mg/kg) or vehicle at 4 and 24 hours after the stroke onset. Infarct volume, neurological deficits, blood-brain barrier integrity, and several inflammatory mediators were examined 48h after tMCAO. Results: The expression level of the BET protein, BRD4, in the cerebral cortex was remarkably lower in the dBET1-treated animals compared to the controls. dBET1 significantly reduced infarct volume (56.2±7.9%, P≤0.01, n=13-14) and improved the neurological performance in the open field test, vertical grid test, and neurological deficit scoring (P≤0.05, n=19-20). In dBET1-treated mice, in both ischemic striatum and cerebral cortex, the inflammation-associated reactive gliosis in astrocytes and microglia was significantly attenuated (P≤0.05, n=6), along with a reduction in stroke-mediated blood-brain barrier damage and neutrophil infiltration. Mechanistically, dBET1 produced a dramatic decrease in the expression levels of pro-inflammatory mediators, while it enhanced levels of anti-inflammatory mediators (P≤0.05, n=6). Conclusion: Overall, this study provides direct in vivo evidence that BET protein degradation with dBET1 suppresses neuroinflammation and leads to anatomical and functional protection against ischemic brain damage. Blocking BET proteins is a promising new strategy to reduce neuroinflammation and eventually improve functional outcomes in stroke.

Role of BET Proteins in Inflammation and CNS Diseases

The BET family in immunity and disease

Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury

Abstract 164: Bet Protein Degradation With The Proteolysis-targeting Chimera, Dbet1, Ameliorates Brain Damage And Neurological Deficits After Transient Cerebral Ischemia

A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles

The Functions of BET Proteins in Gene Transcription of Biology and Diseases

BET protein inhibition promotes non-myeloid cell mediated neuroprotection after rodent spinal cord contusion

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

Precision Targeting of BET Proteins - Navigating Disease Pathways, Inhibitor Insights, and Shaping Therapeutic Frontiers: A Comprehensive Review

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Small-molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential.

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

Bet N-Terminal Bromodomain Inhibition Selectively Blocks Th17 Cell Differentiation And Ameliorates Colitis In Mice

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

<b>Bromodomain and Extra-Terminal Domain Protein 2</b><b>in Multiple Human Diseases</b>

Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases.

The Epigenetic Reader BRD2 as a Specific Modulator of PAI-1 Expression in Lipopolysaccharide-Stimulated Mouse Primary Astrocytes

Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction

Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases

A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4